Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 13/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16279442 | 0.99 | CHRM2 (0.66) | CHRM2CHRM3KMT2AGFERMEN1 | |
| Hydrochloric Acid SCHEMBL1246725 | 0.99 | CHRM2 (0.66) | CHRM2CHRM3KMT2AGFERMEN1 | |
| Trifluoroacetic Acid SCHEMBL1246889 | 0.93 | CHRM2 (0.63) | CHRM2CHRM3KMT2AGFERMEN1 | |
| Trifluoroacetic Acid SCHEMBL2140552 | 0.93 | CHRM2 (0.63) | CHRM2CHRM3KMT2AGFERMEN1 | |
| SCHEMBL1246663 | 0.87 | CHRM2 (0.73) | CHRM2CHRM3KMT2AGFERMEN1 | |
| SCHEMBL10241517 | 0.86 | CHRM2 (0.64) | CHRM2CHRM3GFERHTR2C | |
| Hydrochloric Acid SCHEMBL2139922 | 0.85 | CHRM2 (0.63) | CHRM2CHRM3GFERHTR2C | |
| SCHEMBL15080608 | 0.84 | CHRM2 (0.75) | CHRM2CHRM3 | |
| SCHEMBL10241980 | 0.83 | CHRM2 (0.48) | CHRM2CHRM3KMT2AGFERMEN1 | |
| SCHEMBL1246045 | 0.83 | CHRM2 (0.67) | CHRM2CHRM3KMT2AMEN1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | disclosed |
| US-20160002261-A1 | Process | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002261-A1 | Process | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002261-A1 | Process | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | US | disclosed |
| US-20140364601-A1 | PROCESS | ASTRAZENECA AB (SE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364601-A1 | PROCESS | ASTRAZENECA AB (SE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364601-A1 | PROCESS | ASTRAZENECA AB (SE) | 2014-12-11 | — | — | US | disclosed |
| EP-2707362-A1 | PROCESS | AstraZeneca AB (SE) | 2014-03-19 | — | — | EP | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| WO-2011012897-A1 | NEW COMBINATIONS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012897-A1 | NEW COMBINATIONS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364601-A1 | PROCESS | CYP1A2, CYP3A4, CYP11B2 | CHRM2 3666/4885CHRM3 3835/4885KMT2A 3650/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CHRM2 2419/4885CHRM3 2714/4885KMT2A 4286/4885 |
| US-20160002261-A1 | Process | CYP1A2, CYP11B2, CYP2F1 | CHRM2 3740/4885CHRM3 4106/4885KMT2A 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.